Lung cancer treatment: Pfizer's Lorbrena extends life in ... - NBC News
WEBMay 31, 2024 · Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a ...
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC
WEBJul 10, 2024 · The drug lorlatinib (Lorbrena) is superior to crizotinib (Xalkori) as an initial treatment for people with advanced non-small cell lung cancer (NSCLC) that has changes in the ALK gene, according to new results from a global clinical trial.
FDA Approves New Drug for Non-Small Cell Lung Cancer With …
WEBJan 10, 2024 · The drug Ingrid was given was approved in November 2023 by the Food and Drug Administration (FDA) to treat advanced non-small cell lung cancer with a ROS1 fusion. The approval was based on findings from the trial in …
FDA Approves First Targeted Therapy to Treat Aggressive Form of …
WEBMay 6, 2020 · Today, the U.S. Food and Drug Administration approved Tabrecta (capmatinib) for the treatment of adult patients with non-small cell lung cancer (NSCLC) that has spread to other parts of the...
FDA Approves Osimertinib for Unresectable NSCLC - Medscape
WEB5 days ago · IASLC Issues Consensus on Neoadjuvant, Adjuvant Treatments in Non–Small Cell Lung Cancer Immune-Related Adverse Events Linked to Longer Survival in Patients With Non-Small Cell Lung Cancer ...
Researchers build first large-scale atlas of how immune cells react …
WEB1 day ago · b, Mutational landscape pre-therapy of common somatic mutations in NSCLC (n = 58). Top 3 mutational signature scores by DeconstructSig (SBS1, SBS4, SBS87). Top 3 mutational signature scores by ...
Latest advances in treatment for non-small cell lung cancer - The Lancet
WEBMar 4, 2024 · For advanced stage NSCLC, the number of EMA-approved targeted therapies for patients with metastatic lung cancer have increased rapidly over the past two decades and is expected to continue to grow quickly in the future.
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
WEBApr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC).
New promises and challenges in the treatment of advanced non …
WEBAug 6, 2024 · Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance.
Non-small-cell lung cancer - Latest research and news | Nature
WEB3 days ago · Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different...
- Some results have been removed